Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Haessler · SciRah

Researcher profile · Semantic Scholar

J. Haessler

Share profile

J. Haessler — researcher profile on SciRah

h-index: 13
Works: 40
Citations: 2,392

Most-cited papers

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.
T. Bartel, J. Haessler, T. Brown, J. Shaughnessy +8 more
2009Blood509 citations Open access
Semantic Scholar
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.
R. Walker, B. Barlogie, J. Haessler, G. Tricot +16 more
2007Journal of Clinical Oncology407 citations
Semantic Scholar
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
B. Barlogie, E. Anaissie, F. van Rhee, J. Haessler +16 more
2007British Journal of Haematology334 citations Open access
Semantic Scholar
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.
B. Barlogie, M. Pineda‐Roman, F. van Rhee, J. Haessler +12 more
2008Blood249 citations Open access
Semantic Scholar
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2
M. Pineda‐Roman, M. Zangari, J. Haessler, E. Anaissie +5 more
2008British Journal of Haematology172 citations Open access
Semantic Scholar
An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma.
W. Xiong, Xiao-Song Wu, S. Starnes, Sarah K. Johnson +6 more
2008Blood143 citations Open access
Semantic Scholar
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma
B. Barlogie, E. Anaissie, J. Haessler, F. van Rhee +6 more
2008Cancer129 citations Open access
Semantic Scholar
Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling
J. Haessler, J. Shaughnessy, F. Zhan, J. Crowley +11 more
2007Clinical Cancer Research102 citations Open access
Semantic Scholar
Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.
B. Barlogie, G. Tricot, J. Haessler, F. van Rhee +12 more
2008Blood80 citations Open access
Semantic Scholar
TP53 Deletion is Not an Adverse Feature in Multiple Myeloma Treated with Total Therapy 3
J. Shaughnessy, Yi-Ming Zhou, J. Haessler, F. van Rhee +7 more
2009British Journal of Haematology79 citations Open access
Semantic Scholar
Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival
B. V. Van Ness, Christine Ramos, M. Haznadar, A. Hoering +17 more
2008BMC Medicine60 citations Open access
Semantic Scholar
Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics
J. Shaughnessy, J. Haessler, F. van Rhee, E. Anaissie +10 more
2007British Journal of Haematology53 citations
Semantic Scholar
Eight‐year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1
M. Zangari, F. van Rhee, E. Anaissie, M. Pineda‐Roman +3 more
2008British Journal of Haematology33 citations Open access
Semantic Scholar
Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma
B. Barlogie, J. Haessler, M. Pineda‐Roman, E. Anaissie +6 more
2008Cancer12 citations
Semantic Scholar
Cytogenetic Abnormalities in Multiple Myeloma: Poor Prognosis Linked to Concomitant Detection in Random and Focal Lesion Bone Marrow Samples and Associated with High-Risk Gene Expression Profile
Yi-Ming Zhou, B. Nair, J. Shaughnessy, M. Cartron +5 more
2009British Journal of Haematology8 citations Open access
Semantic Scholar
An Update on the Role of Thalidomide (THAL) in Total Therapy 2 (TT2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Analysis of Subgroups Defined by Standard Prognostic Factors (SPF) and Gene Expression Profiling (GEP)-Derived Subgroups.
J. Shaughnessy, J. Haessler, J. Zeldis, Yong-Sheng Huang +11 more
20068 citations
Semantic Scholar
Total therapy (TT) for myeloma (MM)—10% cure rate with TT1 suggested by >10yr continuous complete remission (CCR): Bortezomib in TT3 overcomes poor-risk associated with T(4;14) and DelTP53 in TT2
B. Barlogie, E. Anaissie, F. van Rhee, J. Shaughnessy +5 more
20085 citations
Semantic Scholar
High-dose melphalan (MEL) based autotransplants (AT) for multiple myeloma (MM): The Arkansas experience since 1989 in more than 2,800 patients
M. Pineda‐Roman, J. Haessler, K. Hollmig, E. Anaissie +6 more
20074 citations
Semantic Scholar
The Genetic Contribution to the Aetiology of Thalidomide Associated VTE.
G. Morgan, David C. Johnson, J. Crowley, J. Shaughnessy +11 more
20063 citations
Semantic Scholar
Outcome with total therapy 3 (TT3) compared to total therapy 2 (TT2): Role of GEP70-defined high-risk disease with trisomy of 1q21 and activation of the proteasome gene PSMD4.
J. Shaughnessy, Ping-Ping Qu, E. Tian, R. Edmondson +7 more
20102 citations
Semantic Scholar
Gene expression profiling (GEP) in multiple myeloma (MM): Distinguishing relapses with high-risk transformation from those with sustained low risk.
J. Sawyer, J. Shaughnessy, J. Haessler, A. Hoering +1 more
20101 citations
Semantic Scholar
Gene expression profiling (GEP) of cd 138-purified plasma cells (pc) in previously treated multiple myeloma (PTMM): Validating prognostic models developed in newly diagnosed MM (NDMM).
Y. Alsayed, J. Haessler, B. Barlogie, J. Crowley +1 more
2009Journal of Clinical Oncology1 citations
Semantic Scholar
Use of bortezomib (BOR) pharmacogenomics (PG) to identify mechanisms of drug resistance and predict survival in multiple myeloma (MM) treated with total therapy 3 (TT3).
J. Shaughnessy, Ping-Ping Qu, J. Haessler, J. Crowley +1 more
2009Journal of Clinical Oncology1 citations
Semantic Scholar
Genomic variation in myeloma : design , content , and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival
B. V. Van Ness, Christine Ramos, M. Haznadar, A. Hoering +17 more
20081 citations
Semantic Scholar
patients treated since 1989 stem-cell mobilization: the Arkansas experience in more than 3000 autotransplantation for multiple myeloma linked to poor hematopoietic Cytogenetically defined myelodysplasia after melphalan-based
Y. Alsayed, A. Hoering, J. Crowley, J. Sawyer +10 more
20130 citations
Semantic Scholar
other imaging techniques and prognostic factors in multiple myeloma F18-fluorodeoxyglucose positron emission tomography in the context of
Terri L Alpe, E. Angtuaco, R. Walker, J. Epstein +5 more
20110 citations
Semantic Scholar
Metaphase cytogenetic abnormalities (M-CA) in multiple myeloma (MM): Examining number of M-CA for survival in total therapy protocols (TT1, TT2, TT3).
J. Haessler, B. Nair, Jeffrey R. Sawyer, A. Hoering +2 more
20100 citations
Semantic Scholar
Defining the prognostic variables in gene expression profiling (GEP)-defined high-risk multiple myeloma (MM): Distinguishing early failures (EF) from sustained control (SC).
B. Barlogie, J. Shaughnessy, J. Haessler, A. Hoering +3 more
20100 citations
Semantic Scholar
Gene Expression Profiling (GEP) of CD138-Purified Plasma Cells: Modeling for High LDH and Cytogenetic Abnormalities as Independently Adverse Features of Multiple Myeloma (MM) In Total Therapy (TT) Protocols
Ping-Ping Qu, J. Haessler, J. Shaughnessy, J. Crowley +1 more
20100 citations
Semantic Scholar
Genomic evolution in total therapy 2 (TT2) and total therapy 3 (TT3) for newly diagnosed multiple myeloma (MM): Comparison of baseline (BL) and relapse (REL) gene expression profiling (GEP) signatures.
A. Hoering, J. Shaughnessy, J. Haessler, R. Sexton +6 more
20100 citations
Semantic Scholar
Bone marrow microenvironment (ME) associated genes identified prior to all altered 48 hours after bortexomib test-dose application and prognosis of multiple myeloma (MM) treated with total therapy 3 (TT3).
Ping-Ping Qu, J. Haessler, B. Barlogie, J. Shaughnessy
2009Journal of Clinical Oncology0 citations
Semantic Scholar
PET and MRI correlation with molecular markers of disease aggressiveness in multiple myeloma
T. Brown, T. Bartel, J. Brown, J. Haessler +6 more
20090 citations
Semantic Scholar
Gene expression profiling (GEP)-defined risk and molecular subgroups assessed at baseline and at relapse: Collective impact on post-relapse survival of multiple myeloma (MM) treated with total therapies 2 and 3.
B. Nair, J. Shaughnessy, Y. Alsayed, J. Haessler +5 more
2009Journal of Clinical Oncology0 citations
Semantic Scholar
MDS-associated cytogenetic abnormalities (MDS-CA) after total therapy (TT) regimens for newly diagnosed multiple myeloma (MM): Apparent surge after introduction of post-transplant consolidation chemotherapy (CONS) in TT2 and TT3.
Klaus Hollmig, S. Waheed, B. Nair, J. Haessler +6 more
2009Journal of Clinical Oncology0 citations
Semantic Scholar
Utility of FDG-PET/CT in detecting extramedullary disease in multiple myeloma patients
A. Itskovich, T. Brown, B. Barlogie, J. Haessler +2 more
20090 citations
Semantic Scholar
Prognostic implications of comprehensive imaging with PET-CT, MRI, and X-rays and their biological and molecular correlates in multiple myeloma (MM) treated with total therapy 3 (TT3).
T. Bartel, T. Brown, J. Haessler, J. Shaughnessy +6 more
2009Journal of Clinical Oncology0 citations
Semantic Scholar
Focal Lesion (FL) Identification by MRI and Metastatic Bone Survey (MBS) in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2 (TT2).
R. Walker, J. Haessler, G. Tricot, J. Shaughnessy +9 more
20060 citations
Semantic Scholar
Testing Standard and Genetic Markers in 220 Patients with Multiple Myeloma (MM) with Complete Data Sets: Superiority of Molecular Genetics.
J. Shaughnessy, J. Haessler, Ichiro Hanamura, Yong-Sheng Huang +12 more
20060 citations
Semantic Scholar
Pompes à chaleur sur la nappe phréatique rhénane: bilan et perspectives après 10 années d'expérience
J. Haessler, M. Becker
19860 citations
Semantic Scholar
Utilisation de la nappe phréatiques pour le chauffage par pompes à chaleur des grands ensembles d'habitat collectif existant
Y. Babot, J. P. Clavequin, A. Cochet, J. Haessler
19830 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

B. Barlogie×32
Invite
B. Barlogie — researcher profile on SciRah
J. Crowley×27
Invite
J. Crowley — researcher profile on SciRah
F. van Rhee×24
Invite
F. van Rhee — researcher profile on SciRah
E. Anaissie×21
Invite
E. Anaissie — researcher profile on SciRah

×20

Invite

J. Shaughnessy — researcher profile on SciRah

M. Pineda‐Roman×16

Invite

M. Pineda‐Roman — researcher profile on SciRah

Invite

J. Epstein — researcher profile on SciRah

Invite

K. Hollmig — researcher profile on SciRah

Invite

M. Zangari — researcher profile on SciRah

Invite

Y. Alsayed — researcher profile on SciRah

Invite

G. Tricot — researcher profile on SciRah

Invite

A. Hoering — researcher profile on SciRah